BioXcel Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
BioXcel Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q3 2024.
  • BioXcel Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -194 %, a 135% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -194 -753 -135% Sep 30, 2024
Q2 2024 -232 -426 -220% Jun 30, 2024
Q1 2024 -342 -451 -415% Mar 31, 2024
Q4 2023 -1.39K -1.45K -2350% Dec 31, 2023
Q3 2023 559 +526 +1571% Sep 30, 2023
Q2 2023 194 +177 +1087% Jun 30, 2023
Q1 2023 109 +102 +1472% Mar 31, 2023
Q4 2022 61.9 +55.3 +837% Dec 31, 2022
Q3 2022 33.5 +27.3 +438% Sep 30, 2022
Q2 2022 16.3 +9.68 +146% Jun 30, 2022
Q1 2022 6.92 -2.33 -25.2% Mar 31, 2022
Q4 2021 6.61 -4.47 -40.3% Dec 31, 2021
Q3 2021 6.22 -9.19 -59.6% Sep 30, 2021
Q2 2021 6.62 -19.6 -74.7% Jun 30, 2021
Q1 2021 9.25 -16.6 -64.2% Mar 31, 2021
Q4 2020 11.1 -19.1 -63.3% Dec 31, 2020
Q3 2020 15.4 -8.3 -35% Sep 30, 2020
Q2 2020 26.2 +9.48 +56.7% Jun 30, 2020
Q1 2020 25.9 +16.2 +169% Mar 31, 2020
Q4 2019 30.2 +23.6 +358% Dec 31, 2019
Q3 2019 23.7 +16.9 +249% Sep 30, 2019
Q2 2019 16.7 Jun 30, 2019
Q1 2019 9.62 Mar 31, 2019
Q4 2018 6.59 Dec 31, 2018
Q3 2018 6.8 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.